Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration have?
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration has 779 citations in the OpenAlex counts ScholarIQ stores.
When was Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration published?
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration has 2012 year in the ScholarIQ index.
What is the open-access status of Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration?
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration has closed oa status in the ScholarIQ index.
What is the DOI of Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration?
The DOI for Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration is on the source record.
What is the PMID of Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration?
The PMID for Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration is on the source record.
What is the OpenAlex record for Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration?
The OpenAlex for Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration is on the source record.